A boy battling Cancer sits on the edge of his hospital bed as he patiently waits for his Chemotherapy treatment to run.
getty
If you look at the infrastructure of modern medicine, from clinical trials to venture capital funding tomorrow’s breakthroughs, one glaring blind spot becomes apparent: children.
Today, roughly one-third (30-33%) of the global population is under the age of 18. Yet pediatric health receives less than 2% of global digital health innovation and venture capital investment. And in the United States specifically, where children represent nearly 24% of the population, they received only 12.8% of the NIH’s 2026 annual budget.
Health systems globally are built for adults. This is particularly true of the American health system. The research pathways, regulatory frameworks, and financial models that drive medical innovation today are designed around adult physiology, adult diseases, and adult purchasing power. And because of it, nearly a quarter of the U.S. population is being left behind in an era of unprecedented medical progress.
The Broken Venture Math
To understand why pediatric innovation is stalled, you have to look at the accounting. Venture capital operates on a straightforward equation: identify a large addressable market, develop a high-margin solution, and deploy it before competitors catch up.
Pediatric medicine breaks every rule in that playbook. The major conditions that afflict children, such as rare genetic disorders, congenital defects, and pediatric cancers, are by definition affecting small patient pools. In fact, a 2025 Frontiers in Public Health study concluded that 80% of rare diseases are attributable to genetic factors. In the eyes of traditional venture models, a therapy targeting a disease that affects one in 50,000 children doesn’t offer the 10x or 30x returns investors desire to justify their risk capital.
However, the sector’s history of underinvestment has inadvertently created the conditions for an outsized opportunity, according to the Milken Institute. And John Parker, Founder and Managing Partner of Springhood Ventures, a pediatric-focused venture fund, and a trustee of the Charles H. Hood Foundation, agrees. He contends that the market has simply been asleep at the wheel. “The assumption was that the markets were too small, the trials too hard to run, the economics too thin. What that underinvestment actually did was let unmet need pile up while the science kept advancing in the background,” Parker says. “Today you have massive unmet need, a wave of great technology, real regulatory and economic incentives, and valuations that reflect a sector the market hasn’t caught up to yet.”
Additionally, one could argue that in 2026, the increased development of personal biomarkers and one-of-a-kind treatments is narrowing many patient pools, making small populations more common. The math is essentially changing alongside precision medicine. Pediatric innovation generates extraordinary returns because the impact of earlier intervention is seen through a lifetime of health span. No other segment delivers similar long-term value, yet it remains treated as an afterthought to adult care.
The Caregiver Burden And Policy Fixes
The burden of pediatric illness rarely falls evenly. It disproportionately falls onto mothers, creating a devastating, generational “caregiver tax.” When children face chronic conditions or rare diseases, parents are frequently forced to leave the workforce to become full-time case managers, caregivers, and advocates. And unfortunately, current “Families First” political rhetoric keeps treating the logistics of this crisis rather than the root cause. Universal pre-K, parental leave, and childcare subsidies are vital supports, but they only matter when there is a treatable condition to manage.
And ultimately, the answers these parents need come down to science and funding. But it might surprise many to learn just how much the regulatory pathways are helping the science side of the equation. Yes, children are classified as a “vulnerable population” under federal research guidelines, which can delay recruitment and create numerous IRB challenges. But in recent years, regulatory bodies have shown a willingness to work with innovators.
For example, Congress passed the Food and Drug Administration Safety and Innovation Act (FDASIA), which included the Creating Hope Act to establish the Rare Pediatric Disease Priority Review Voucher (PRV) program. This legislation expanded the existing PRV system, originally created in 2007 for neglected tropical diseases, to incentivize the development of treatments for serious or life-threatening diseases affecting children. Under this program, small biotech companies that successfully attain FDA approval for a drug addressing a rare pediatric condition will receive a transferable voucher allowing them to expedite the review of another drug application from 10 months to 6 months. These vouchers can be sold to a large pharmaceutical company, with recent value surpassing $150 million for a single voucher. The value of a potential voucher can change the math for venture capital funds assessing returns on an investment in an early-stage company. Although the PRV program expired in 2024, it was just renewed through 2029, signaling a continued attempt to bridge the financial gap in children’s health.
Bridging the Gap
Fixing the adults-first bias requires changing not just our models, but our thinking, and our action. This includes expanded federal grants, IRB harmonization, and new models of capital deployment. And there are a wide range of experts beginning to step into the space, changing the investment conversation. From broad-ranging, patient-led rare disease efforts like the Buffalo Initiative to disease-specific fundraising for children at Finding Hope for Frizzle, new entrants are prioritizing children.
Rachel E. Butler, President of the Catalytic Impact Foundation (CIF), calls for a holistic view to help tackle the ongoing funding gaps. As she explains, “Women’s health, maternal health, children’s health, and rare disease are not separate funding gaps. They are connected areas where traditional capital has historically moved too slowly. CIF’s regenerative philanthropy model is designed to fill that gap by investing philanthropic capital into emerging life science companies, then reinvesting returns into future high-impact innovation.”
The Foundation’s model, investing early to de-risk and exit strategically, is born out of a specific realization regarding the financial status quo. Richard Lipkin, Founder of CIF, said that, “Seeing families of children with rare diseases suffer so profoundly, while potential therapies languish, unfunded, was outrageous and frustrating. I realized that we need a different system to develop transformative solutions—to bridge the gap, the mismatch, between the needs of suffering families and those of investors.”
The era of treating pediatric innovation as an afterthought is finally yielding to a new reality where early intervention delivers compounding health and economic returns. As regenerative philanthropy, targeted venture funds, and renewed regulatory incentives begin aligning with unmet needs, the financial barriers that have sidelined pediatric research can rapidly move. Redirecting capital toward childhood-onset conditions accelerates science, decreases caregiver burden, and unlocks decades of productive life for the next generation. Closing this funding gap is no longer a question of whether the market can afford to invest in children, but whether we can afford not to.